Details

Autor(en) / Beteiligte

• Chiuppesi, Flavia
• Salazar, Marcela d'Alincourt
• Contreras, Heidi
• Nguyen, Vu H
• Martinez, Joy
• Park, Yoonsuh
• Nguyen, Jenny
• Kha, Mindy
• Iniguez, Angelina
• Zhou, Qiao
• Kaltcheva, Teodora
• Levytskyy, Roman
• Ebelt, Nancy D
• Kang, Tae Hyuk
• Wu, Xiwei
• Rogers, Thomas F
• Manuel, Edwin R
• Shostak, Yuriy
• Diamond, Don J
• Wussow, Felix

Titel

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

Ist Teil von

• Nature communications, 2020-11, Vol.11 (1), p.6121-6121, Article 6121

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.